This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janmaat, M. L. Articles by Giaccone, G. Search for Related Content PubMed PubMed Citation Articles by Janmaat, M. L. Articles by Giaccone, G.

Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

Correspondence: Giuseppe Giaccone, M.D., Ph.D., Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, PO Box 7057, MB 1007 Amsterdam, The Netherlands. Telephone: 31-20-444-4340; Fax: 31-20-444-3844; e-mail: g.giaccone{at}vumc.nl

The growth and proliferation of cells are usually tightly regulated processes that are activated by stimuli from their environment. Epidermal growth factor (EGF)-related peptides represent a class of molecules that can trigger cell proliferation, among several cellular processes, such as differentiation, migration, and survival. Binding of EGF-like peptides to the EGF receptor (EGFR) at the cell surface leads to a cascade of intracellular reactions that transduce signals to the nucleus, resulting in particular gene expression patterns. However, in many tumor cells, the regulation of EGFR activity is lost, due to increased or aberrant expression of the receptor or its ligands, and this contributes to many processes important for tumor growth, including cell proliferation, survival, angiogenesis, invasion, and metastasis. Many strategies have been developed that specifically target the EGFR and inhibit its activity. Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising classes of anticancer agents. Here, we describe the status of small-molecule EGFR tyrosine kinase inhibitors in preclinical and clinical development.

Key Words. EGFR • ZD1839 • Iressa • OSI-774 • Tarceva

This article has been cited by other articles:

				S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417. [Abstract] [Full Text] [PDF]

				Y. Ning, R. Zeineldin, Y. Liu, M. Rosenberg, M. S. Stack, and L. G. Hudson Down-regulation of Integrin {alpha}2 Surface Expression by Mutant Epidermal Growth Factor Receptor (EGFRvIII) Induces Aberrant Cell Spreading and Focal Adhesion Formation Cancer Res., October 15, 2005; 65(20): 9280 - 9286. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, and M. R. Freeman Trafficking of Nuclear Heparin-Binding Epidermal Growth Factor-like Growth Factor into an Epidermal Growth Factor Receptor-Dependent Autocrine Loop in Response to Oxidative Stress Cancer Res., September 15, 2005; 65(18): 8242 - 8249. [Abstract] [Full Text] [PDF]

				J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070. [Abstract] [Full Text] [PDF]